• TILs for the Treatment of Solid Tumors with KSQ Therapeutics' Micah Benson, Ph.D.

  • Jul 4 2024
  • Length: 36 mins
  • Podcast

TILs for the Treatment of Solid Tumors with KSQ Therapeutics' Micah Benson, Ph.D.

Listen for free

View show details

  • Summary

  • We love to hear from our listeners. Send us a message.

    KSQ Therapeutics' CSO, Micah Benson, Ph.D., joins Erin Harris to discuss how Tumor-Infiltrating Lymphocytes (TILs) as a treatment modality have the potential to treat a variety of solid tumor types. Benson explains KSQ's Phase 1/2 clinical study, KSQ-001EX, which consists of TILs in which the SOCS1 gene is inactivated by CRISPR/Cas9 gene editing. In addition to solid tumors, Benson also addresses the therapeutic potential for autoimmune disease.
    Show more Show less
activate_Holiday_promo_in_buybox_DT_T2
Show more Show less

What listeners say about TILs for the Treatment of Solid Tumors with KSQ Therapeutics' Micah Benson, Ph.D.

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available